Beclomethasone for graft versus host disease – pro
The pathological and clinical findings of gastrointestinal (GI) graft-versus-host disease (GVHD) are similar to those of inflammatory bowel disease. Three previous studies had shown the safety and efficacy of the topical BDP for GI GVHD. It is possibe that it would function similarly for GVHD. Several small pahse IIs tudies suggest that it suppresses allogeneic immune responses in the gut without causing significant immunosuppression.
This therapy is under study: Compassionate Use of Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Gastrointestinal Tract, NCT00055666.
G.McDonald, M.Bouvier, D.Hockenbery, J.Stern, T.Gooley, A.Farrand, C.Murakami, D.Levine
Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: A randomized, controlled trial Gastroenterology, Volume 115, Issue 1, Pages 28-35
Y Miura et al, Oral beclomethasone dipropionate as an initial treatment of gastrointestinal acute graft-versus-host disease after reduced-intensity cord blood transplantation Bone Marrow Transplantation (2006) 38, 577–579.